The Latest Cardiac and Vascular News
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2021 fourth quarter ended September 30, 2021 and provided its financial outlook for its fiscal 2022. Summary of Fourth Quarter and Recent […]
Collaboration will empower clinicians with AI-enhanced diagnostics for heart failure and coronary artery disease beyond the walls of the hospital BRISBANE, Calif., OXFORD, England and GUILFORD, Conn., Nov. 9, 2021 /PRNewswire/ — Caption Health and Ultromics, leaders in using AI to improve heart ultrasound diagnostics, today announced a strategic partnership to accelerate cardiovascular disease detection […]
ScanWatch, which received FDA clearance for atrial fibrillation detection through ECG and measuring SpO2 levels from the wrist, becomes available in the United States ISSY-LES-MOULINEAUX, France, Nov. 9, 2021 /PRNewswire/ — Today, Withings, pioneers of the connected health revolution, begins U.S. sales of ScanWatch, its award-winning and most advanced health wearable to date. Available from […]
SANTA CLARA, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended September 30, 2021. Recent Highlights Recognized revenue of $65.2 million […]
THE WOODLANDS, Texas, Nov. 09, 2021 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that a new analysis of sotagliflozin results from the SOLOIST and SCORED Phase 3 outcomes studies will be presented at the virtual American Heart Association Scientific Sessions 2021. The new analysis will be presented by Deepak […]
All additional testing of devices manufactured on the planned commercial line, as required by the FDA, has been successful to date FUROSCIX® NDA resubmission anticipated for Q1 2022 due to COVID-19 related global supply chain logistics interruptions and travel restrictions Revised NDA resubmission timeline is not expected to have an […]
Interim analysis data for Phase 2b clinical trials of tovinontrine (IMR-687) in patients with beta-thalassemia and sickle cell disease expected in fourth quarter of 2021 Introduction of pipeline program IMR-261, a novel oral clinic-ready Nrf2 activator shown to reactivate fetal hemoglobin and reduce VOCs in preclinical models of sickle cell disease Building […]
MINNEAPOLIS, Nov. 09, 2021 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the third quarter ended September 30, 2021, which included the following highlights: Generated $1.9 million in total revenue, representing a decline of 3% compared to the prior-year period Generated $6.3 million in total revenue […]
ANGPTL3 Base Editor Delivered via Internally Developed GalNAc-LNPs Potently Reduced Blood ANGPTL3 Protein by 94-97% in a Novel NHP Model of Homozygous Familial Hypercholesterolemia GalNAc-LNP Delivery of ANGPTL3 Base Editor Led to Potent Editing in both LDLR-Deficient and Normal NHP Livers, Supporting Potential Broad Applicability CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE […]
-CGuard™ sales generated 24% YoY revenue growth- -CGuard™ EPS received a positive opinion from the French National Authority for Health (HAS) regarding reimbursement in France- – $37.1 million in cash, cash equivalents and short-term bank deposits as of September 30, 2021, provides runway into first half of 2023- -Management to […]
